Balapiravir hydrochloride
Based on 5 publication(s) in Google Scholar
Balapiravir hydrochloride (Ro 4588161 hydrochloride; R1626 hydrochloride) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir hydrochloride has anti-HCV activity. Balapiravir (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
For research use only. We do not sell to patients.
- CAS No.: 690270-65-6
- Formula: C21H31ClN6O8
- Molecular Weight:530.96
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Balapiravir hydrochloride
MoreAll DNA/RNA Synthesis Isoforms
More
Biological Activity
|
RNA Polymerase |
After oral dosing of the CD-1 mice with 28.1 mg/kg of balapiravir (Ro 4588161 hydrochloride; R1626 hydrochloride), R1479 reaches a Cmax and a minimum concentration in plasma (Cmin) of 24.38 μM and 6.34 μM, respectively, at 2 h and 24 h postdosing[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 690270-65-6
-
Molecular Weight 530.96
-
Formula C21H31ClN6O8
-
SMILES
O=C1N=C(N)C=CN1[C@@H]2O[C@](N=[N+]=[N-])(COC(C(C)C)=O)[C@@H](OC(C(C)C)=O)[C@H]2OC(C(C)C)=O.Cl
-
Synonyms
Ro 4588161 hydrochloride; R1626 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
J Biomed Sci
Targeting a genomic RNA G-quadruplex of dengue virus with small molecules as an alternative to protein-targeted therapeutics. [Abstract]2026 May 27;33(1):55. PMID: 42204560 -
Antiviral Res
Antiviral candidates against the hepatitis E virus (HEV) and their combinations inhibit HEV growth in in vitro. [Abstract]2019 Oct:170:104570. PMID: 31362004 -
Antiviral Res
Structure-activity relationships of nucleoside analogues for inhibition of tick-borne encephalitis virus. [Abstract]2016 Sep:133:119-29. PMID: 27476046 -
J Infect Dis
2016 Sep 1;214(5):707-11. PMID: 27234417 -
J Med Virol
Drug Repurposing: In Vitro Evaluation of Simeprevir as a Novel Antiviral Drug Against Severe Fever With Thrombocytopenia Syndrome Virus. [Abstract]2025 Oct;97(10):e70655. PMID: 41117261
Purity & Documentation
References
[1]. Nguyen NM, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis. 2013 May 1;207(9):1442-1450. [Content Brief]
[2]. Nelson DR, et al. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.Ann Hepatol. 2012 Jan-Feb;11(1):15-31. [Content Brief]
[3]. Yen-Liang Chen, et al. Activation of Peripheral Blood Mononuclear Cells by Dengue Virus Infection Depotentiates Balapiravir. J Virol. 2014 Feb;88(3):1740-7. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Balapiravir hydrochloride Related Classifications
HY-10443A Related Classifications
Powered by Bioz